Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Molecular and Cellular Cardiology|December 1, 1989
Decrease with senescence in the norepinephrine-induced phosphorylation of myofilament proteins in isolated rat cardiac myocytesM Sakai, R S Danziger, J M Staddon, et al.
Journal of Gerontology|September 1, 1990
Effects of age and adenosine in the modulation of insulin action on rat adipocyte metabolismG C Rolband, E D Furth, J M Staddon, et al.
The Biochemical Journal|February 5, 2000
Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cellsE Y Wong, L Morgan, C Smales, et al.
FEBS Letters|December 17, 1990
Sequence analysis of the potent mitogenic toxin of Pasteurella multocidaA J Lax, N Chanter, G D Pullinger, et al.
Analytical Biochemistry|December 20, 1999
Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitorsC Bardelle, C Smales, M Ito, et al.
The Journal of Biological Chemistry|January 15, 2001
Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanismsT Hirase, S Kawashima, E Y Wong, et al.
The Journal of Biological Chemistry|March 15, 1991
Pasteurella multocida toxin, a potent mitogen, increases inositol 1,4,5-trisphosphate and mobilizes Ca2+ in Swiss 3T3 cellsJ M Staddon, C J Barker, A C Murphy, et al.
Journal of Cell Science|July 1, 1997
Occludin as a possible determinant of tight junction permeability in endothelial cellsT Hirase, J M Staddon, M Saitou, et al.
Neuroscience|June 15, 2007
Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosisL Morgan, B Shah, L E Rivers, et al.
Journal of Neuroimmunology|July 17, 1999
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitorsV A Folcik, T Smith, S O'Bryant, et al.
Pageof 3